Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, Gonzalez de Leon C, Kim EE, Madden T, Wallin B, Hord M, Verschraegen C, Raber M, Kavanagh JJ.
Kudelka AP, et al.
J Clin Oncol. 1996 May;14(5):1552-7. doi: 10.1200/JCO.1996.14.5.1552.
J Clin Oncol. 1996.
PMID: 8622071
Clinical Trial.